Skip to content

BioCorRx Inc.: 10-Q filed 2023-05-15

What BioCorRx Inc. reported in its quarterly report filed 2023-05-15 (fiscal Q1 2023): 36 published measures, 76 facts as tagged in accession 0001477932-23-003594.

This filing

Form
10-Q (quarterly report)
Filed
2023-05-15
Fiscal period
fiscal Q1 2023
Accession
0001477932-23-003594 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioCorRx Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-03-31709,161USD
At 2022-12-31766,594USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-03-319,536,260USD
At 2022-12-318,968,325USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-03-31-8,700,908USD
At 2022-12-31-8,076,474USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-1,010,586USD90
2022-01-01 to 2022-03-31-944,991USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-397,355USD90
2022-01-01 to 2022-03-31-872,672USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-01-01 to 2023-03-3140,442USD90
2022-01-01 to 2022-03-3120,518USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-03-31532,427USD90
2022-01-01 to 2022-03-311,000,000USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-03-31-75,345,757USD
At 2022-12-31-74,336,105USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-01-01 to 2023-03-311,798,977shares90
2022-01-01 to 2022-03-311,072,078shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-03-3170,202USD
At 2022-12-3176,572USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-03-3179,218USD90
2022-01-01 to 2022-03-31152,912USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-1,056,315USD90
2022-01-01 to 2022-03-31-1,124,674USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-03-31344,426USD
At 2022-12-31316,910USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-01-01 to 2023-03-3126,040USD90
2022-01-01 to 2022-03-3113,276USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-03-315,852,968USD
At 2022-12-315,363,792USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-03-312,189,501USD
At 2022-12-312,013,250USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-01-01 to 2023-03-311,096,757USD90
2022-01-01 to 2022-03-311,145,192USD90

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-01-01 to 2023-03-318,676USD90
2022-01-01 to 2022-03-311,535USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-03-31237,387USD90
2022-01-01 to 2022-03-31197,849USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-03-318,102,173shares
At 2022-12-317,718,636shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-03-31203,687USD
At 2022-12-3168,615USD
At 2022-03-31213,166USD
At 2021-12-3185,838USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-03-3166,815,130USD
At 2022-12-3166,130,296USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-03-31-8,827,099USD
At 2022-12-31-8,201,731USD
At 2022-03-31-6,753,555USD
At 2021-12-31-6,961,476USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-03-31240,102USD
At 2022-12-31270,406USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-03-31283,307USD
At 2022-12-31315,671USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-03-31194,551USD
At 2022-12-31194,551USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-03-31124,349USD
At 2022-12-31117,979USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-03-311,010,586USD90
2022-01-01 to 2022-03-31944,991USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-03-31796,049USD90
2022-01-01 to 2022-03-31938,945USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-03-316,370USD90
2022-01-01 to 2022-03-316,568USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-03-3145,729USD90
2022-01-01 to 2022-03-31179,683USD90

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2023-01-01 to 2023-03-310USD90
2022-01-01 to 2022-03-310USD90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-03-310USD90
2022-01-01 to 2022-03-310USD90

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-01-01 to 2023-03-310USD90
2022-01-01 to 2022-03-310USD90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-03-31300,000USD90
2022-01-01 to 2022-03-311,000,000USD90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-23,163USD90
2022-01-01 to 2022-03-318,893USD90

Inspect the source

Entity
BioCorRx Inc. / CIK 0001443863
Captured
2026-09-20T09:04:22.712Z
SEC response SHA-256
ac5d4257d7a196e773d03095d841b6e99a8b7a937efc54ce0410975e44478703

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001443863.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))